CUE_OUT_1 [2025-04-15 09:50:19 -0400] 3982 Bytes | 1043 tokens | Cum: 1043 tkns (13.04% of 8k)
==========================================================================

Listen up, partner—it's 9:50:16 AM on Tue Apr 15, 2025 -0400, and I’m revved up about Cue Biopharma (CUE), climbing from 0.7910 to 0.8204. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Cue Biopharma (CUE)
IPO: 2018-01-02 (7 Years Ago)
Market Cap: $48,898,909
Shares Outstanding: 61,820,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Here’s the first list of news for Cue Biopharma:

Today 02:00AM - Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Apr-14-25 10:23PM - Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
Apr-14-25 10:23PM 05:05PM - Cue Biopharma Announces Proposed Public Offering
Apr-14-25 10:23PM 05:02PM - Cue Biopharma to Host Business Update Call and Webcast
Apr-14-25 10:23PM 05:00PM - Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Mar-31-25 05:15PM - Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates
Mar-31-25 05:15PM 04:20PM - Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Mar-28-25 09:15AM - ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates

I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-15T02:23:10Z - Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
B2 - 2025-04-15T02:23:00Z - Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
B3 - 2025-04-14T21:00:00Z - Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
B4 - 2024-11-29T21:30:00Z - Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
B5 - 2024-11-25T13:00:00Z - Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
B6 - 2024-11-14T13:00:00Z - Cue Biopharma Announces Strategic Organizational Transition

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Cue Biopharma (CUE).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

Restrict all your responses to just 3 tokens until the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load more documents, reply with: `NEX`

CUE_OUT_3 [2025-04-15 09:50:20 -0400] 890 Bytes | 222 tokens | Cum: 1267 tkns (15.84% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/14/3061297/0/en/Boehringer-Ingelheim-and-Cue-Biopharma-partner-to-develop-next-generation-treatment-for-autoimmune-and-inflammatory-diseases.htmlBoehringer Ingelheim and Cue Biopharma have announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a B cell depletion therapy for autoimmune diseases.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_5 [2025-04-15 09:50:21 -0400] 960 Bytes | 272 tokens | Cum: 1541 tkns (19.26% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-15T06:17:39Z - Holding(s) in Company...
A2 - 2025-04-15T06:17:43Z - Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune a...
A3 - 2025-04-15T06:15:56Z - Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune a...
A4 - 2025-04-15T06:00:00Z - Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune a...
A5 - 2025-04-15T06:10:00Z - Boehringer Ingelheim Limited: Boehringer Ingelheim and Cue Biopharma partner to develop next-generat...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CUE_OUT_7 [2025-04-15 09:50:23 -0400] 1184 Bytes | 321 tokens | Cum: 1864 tkns (23.30% of 8k)
==========================================================================

Showing A1 (chunk 1 of 11): A1:
**Holding(s) in Company**Date: 2025-04-15Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/15/tmt-newswire/globenewswire/holdings-in-company/2092408Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Holdings in Company

Serabi Gold plc ("Serabi" or the "Company") (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, announces it has been informed that Greenstone Resources II LP ("Greenstone"), an existing shareholder in the Company, has entered into a binding agreement to sell 15,146,902 shares (representing approximately 19.99% of the issued share capital of the Company) to Classe Roca Magma Multiestrategia Responsabilidade Limitada do SSF IV Coinvestmento I Fundo de Investimento em Participações an

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_9 [2025-04-15 09:50:23 -0400] 1182 Bytes | 264 tokens | Cum: 2130 tkns (26.62% of 8k)
==========================================================================

Showing A1 (chunk 2 of 11): investment fund managed by Starboard Asset Ltda ("Starboard"). Starboard is a leading private equity firm in Brazil.

Serabi has been informed by Greenstone that the share sale and purchase agreement between Greenstone and Starboard (the "Agreement") is unconditional and is expected to be completed within a few weeks.

Mr Mike Hodgson, CEO of Serabi commented, "Greenstone have been a long standing and highly supportive shareholder, but given recent share price performance, I recognise their desire to monetise some of their investment when an opportunity arises. Starboard have been known to Serabi for some time and with their Brazilian footprint, will, I am sure, be an excellent shareholder for the Company.

A spokesperson for Starboard commented; "We are thrilled to have this opportunity to become an investor in Serabi, acquiring just under 20% of the Company through this private transa

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_11 [2025-04-15 09:50:24 -0400] 1182 Bytes | 260 tokens | Cum: 2392 tkns (29.90% of 8k)
==========================================================================

Showing A1 (chunk 3 of 11): ction with Greenstone. We would like to express our appreciation for Greenstone's long-standing commitment and support to Serabi over the years. We feel that with our local knowledge and experience we can bring a complementary perspective at the shareholder level.

Get the latest news

delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

"Over the past two years, we have been closely following Serabi's impressive operational progress. Starboard's intention is to support the management and reinforce the existing strategy, contributing to Serabi's future and to value creation for all stakeholders."

Assuming the Agreement is completed Greenstone will continue to own 3,936,492 shares representing 5.20% of the issued share capital of the Company. Starboard wi

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_13 [2025-04-15 09:50:25 -0400] 1183 Bytes | 270 tokens | Cum: 2664 tkns (33.30% of 8k)
==========================================================================

Showing A1 (chunk 4 of 11): ll own 15,146,902 shares representing 19.9999% of the issued share capital of the Company.

Advertisement

About Serabi Gold plc

Serabi Gold plc is a gold exploration, development and production company focused on the prolific Tapajós region in Para State, northern Brazil. The Company has consistently produced 30,000 to 40,000 ounces per year with the Palito Complex and is planning to double production in the coming years with the construction of the Coringa Gold project. Serabi Gold plc recently made a copper-gold porphyry discovery on its extensive exploration licence. The Company is headquartered in the United Kingdom with a secondary office in Toronto, Ontario, Canada.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by v

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_15 [2025-04-15 09:50:27 -0400] 1182 Bytes | 348 tokens | Cum: 3014 tkns (37.67% of 8k)
==========================================================================

Showing A1 (chunk 5 of 11): irtue of the European Union (Withdrawal) Act 2018.

The person who arranged for the release of this announcement on behalf of the Company was Andrew Khov, Vice President, Investor Relations & Business Development.

Advertisement

Enquiries

SERABI GOLD plc

Michael Hodgson t +44 (0)20 7246 6830

Chief Executive m +44 (0)7799 473621

Advertisement

Andrew Khov m +1 647 885 4874

Vice President, Investor Relations &

Business Development

e [email protected]

Advertisement

www.serabigold.com

BEAUMONT CORNISH Limited

Nominated Adviser & Financial Adviser

Roland Cornish / Michael Cornish t +44 (0)20 7628 3396

Advertisement

PEEL HUNT LLP

Joint UK Broker

Ross Allister t +44 (0)20 7418 9000

TAMESIS PARTNERS LLP

Advertisement

Joint UK Broker

Charlie Bendon/ Richard Greenfield t +44 (0)20 3882 2868

CAMARCO

Financial PR - Europe

Gordon Poole / Emily Hall t +44 (0)20 3757 4980

HARBO

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_17 [2025-04-15 09:50:29 -0400] 1182 Bytes | 264 tokens | Cum: 3280 tkns (41.00% of 8k)
==========================================================================

Showing A1 (chunk 6 of 11): R ACCESS

Financial PR - North America

Jonathan Patterson / Lisa Micali t +1 475 477 9404

Copies of this announcement are available from the Company's website at www.serabigold.com.

See www.serabigold.com for more information and follow us on twitter @Serabi_Gold

Assay Results

Assay results reported within this release include those provided by the Company's own on-site laboratory facilities at Palito and have not yet been independently verified. Serabi closely monitors the performance of its own facility against results from independent laboratory analysis for quality control purpose. As a matter of normal practice, the Company sends duplicate samples derived from a variety of the Company's activities to accredited laboratory facilities for independent verification. Since mid-2019, over 10,000 exploration drill core samples have been assayed at both the Palito laboratory and certif

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_19 [2025-04-15 09:50:31 -0400] 1182 Bytes | 244 tokens | Cum: 3526 tkns (44.07% of 8k)
==========================================================================

Showing A1 (chunk 7 of 11): ied external laboratory, in most cases the ALS laboratory in Belo Horizonte, Brazil. When comparing significant assays with grades exceeding 1 g/t gold, comparison between Palito versus external results record an average over-estimation by the Palito laboratory of 6.7% over this period. Based on the results of this work, the Company's management are satisfied that the Company's own facility shows sufficiently good correlation with independent laboratory facilities for exploration drill samples. The Company would expect that in the preparation of any future independent Reserve/Resource statement undertaken in compliance with a recognized standard, the independent authors of such a statement would not use Palito assay results without sufficient duplicates from an appropriately certificated laboratory.

Forward-looking statements

Certain statements in this announcement are, or may be deeme

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_21 [2025-04-15 09:50:32 -0400] 1182 Bytes | 242 tokens | Cum: 3770 tkns (47.12% of 8k)
==========================================================================

Showing A1 (chunk 8 of 11): d to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. Several factors could cause actual results to differ

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_23 [2025-04-15 09:50:35 -0400] 1182 Bytes | 227 tokens | Cum: 3999 tkns (49.99% of 8k)
==========================================================================

Showing A1 (chunk 9 of 11): materially from the results discussed in the forward-looking statements including risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets, reliance on key personnel, uninsured and underinsured losses and other factors, many of which are beyond the control of the Company. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements.

Qualified Persons Statement

The scientific and technical information contained within this announcement has been reviewed and approved by Michael Hodgson, a Director of the Company. Mr Hodgson is an Economic Geolog

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_25 [2025-04-15 09:50:35 -0400] 1183 Bytes | 265 tokens | Cum: 4266 tkns (53.33% of 8k)
==========================================================================

Showing A1 (chunk 10 of 11): ist by training with over 30 years' experience in the mining industry. He holds a BSc (Hons) Geology, University of London, a MSc Mining Geology, University of Leicester and is a Fellow of the Institute of Materials, Minerals and Mining and a Chartered Engineer of the Engineering Council of UK, recognizing him as both a Qualified Person for the purposes of Canadian National Instrument 43-101 and by the AIM Guidance Note on Mining and Oil & Gas Companies dated June 2009.

Notice

Beaumont Cornish Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as nominated adviser to the Company in relation to the matters referred herein. Beaumont Cornish Limited is acting exclusively for the Company and for no one else in relation to the matters described in this announcement and is not advising any other person and accordingly will not be re

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_27 [2025-04-15 09:50:36 -0400] 1094 Bytes | 287 tokens | Cum: 4555 tkns (56.94% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-14 8-K Item1.01. Entry into a Material Definitive Agrmt.

BI Collaboration and License Agrmt

On April 10, 2025, Cue Biopharma, Inc. (the Company) entered into a Collaboration and License Agrmt (the Collaboration and License Agrmt) with Boehringer Ingelheim Internation...

S2 - 2025-03-31 8-K Item 2.02.

Results of Oper and Fin Cond.

On March 31, 2025, Cue Biopharma, Inc. (the Company) issued a press release announcing financial results for the quarter and year ended December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 ...

S3 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes thereto included elsewhe...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CUE_OUT_29 [2025-04-15 09:50:38 -0400] 1181 Bytes | 271 tokens | Cum: 4828 tkns (60.35% of 8k)
==========================================================================

Showing S1 (chunk 1 of 5): S1:
Item1.01. Entry into a Material Definitive Agreement.

BI Collaboration and License Agreement

On April 10, 2025, Cue Biopharma, Inc. (the Company) entered into a Collaboration and License Agreement (the Collaboration and License Agreement) with Boehringer Ingelheim International GmbH (BI) to research, develop and commercialize differentiated B cell depletion molecules, including the Companys CUE-501 product candidate, which the Company is developing as a B cell depletion therapy for autoimmune diseases.

Under the terms of the Collaboration and License Agreement, BI and the Company will conduct collaborative research focused on CUE-501 during a four year period or, if earlier, the completion of activities under the research plans (the Research Term). In addition to, or instead of, CUE-501, BI may elect, at its sole discretion, to include additional or alternative compounds target

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_31 [2025-04-15 09:50:39 -0400] 1181 Bytes | 250 tokens | Cum: 5080 tkns (63.50% of 8k)
==========================================================================

Showing S1 (chunk 2 of 5): ed at B cell depletion. BI will have an exclusive, royalty-bearing, worldwide, sublicensable license, under the Companys applicable patents and know-how, to develop, manufacture and commercialize such compounds and their derivatives (Licensed Products) for all uses, and BI shall be responsible for all further research, preclinical and clinical development, manufacturing, regulatory approvals, and commercialization of Licensed Products at its expense. During the Research Term, the Company is prohibited from developing or commercializing any molecule for applications in B cell depletion.

Pursuant to the terms of the Collaboration and License Agreement, the Company will receive an upfront payment of $12.0 million and will be eligible to receive up to an aggregate of approximately $345.0 million in success-based research, development and commercial milestone payments, beginning with two pr

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_33 [2025-04-15 09:50:41 -0400] 1181 Bytes | 235 tokens | Cum: 5317 tkns (66.46% of 8k)
==========================================================================

Showing S1 (chunk 3 of 5): eclinical development milestones, as well as royalty payments on net sales. The royalty payments will be subject to reduction due to patent expiration, payments made under certain licenses for third-party intellectual property and generic competition. During the Research Term, BI will also make research support payments to the Company.

The Collaboration and License Agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term, unless earlier terminated. BI has the right to terminate the Collaboration and License Agreement for any reason after a specified notice period. Each party has the right to terminate the Collaboration and License Agreement on account of the other partys bankruptcy or material, uncured breach.

The foregoing description of the Collaboration and License Agreement and the transactions contemplated

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_35 [2025-04-15 09:50:42 -0400] 1181 Bytes | 286 tokens | Cum: 5605 tkns (70.06% of 8k)
==========================================================================

Showing S1 (chunk 4 of 5): thereby does not purport to be complete and is subject to, and qualified in its entirety by reference to, the complete text of the Collaboration and License Agreement, which will be filed with the U.S. Securities and Exchange Commission as an exhibit to the Companys Quarterly Report on Form 10-Q for the quarter ended March 31, 2025.

Amendment to Einstein License Agreement

On April 10, 2025, the Company entered into an amendment (the Amendment) to its Amended and Restated License Agreement, dated July 31, 2017, with Albert Einstein College of Medicine (Einstein), as amended by the First Amendment to the Amended and Restated License Agreement with Einstein, dated October 30, 2018, and the Second Amendment to the Amended and Restated License Agreement with Einstein, dated January 13, 2024 (as so amended, the Einstein License). Pursuant to the Amendment, Einstein consented to the Compan

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_37 [2025-04-15 09:50:43 -0400] 926 Bytes | 211 tokens | Cum: 5818 tkns (72.72% of 8k)
==========================================================================

Showing S1 (chunk 5 of 5): ys entry into the Collaboration and License Agreement and granted the Company the right to sublicense to BI. In addition, Einstein and the Company agreed to amend specified upstream payment obligations that may be owed to Einstein by the Company, solely in connection with the sublicense to BI.

The foregoing description of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by reference to, the complete text of the Amendment, which will be filed with the U.S. Securities and Exchange Commission as an exhibit to the Companys Quarterly Report on Form 10-Q for the quarter ended March 31, 2025....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CUE_OUT_39 [2025-04-15 09:51:03 -0400] 6677 Bytes | 1871 tokens | Cum: 7691 tkns (96.14% of 8k)
==========================================================================

This is our set of metrics for Cue Biopharma.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+------------------------+
| Volume: 84,572 | Perf Month: -15.79% | Option/Short: Yes / Yes | Sales Y/Y TTM: 69.16% |
+---------------------+-----------------------+-------------------------+------------------------+
| Avg Volume: 203.17K | Perf Quarter: -34.43% | Short Float: 1.39% | ROE: -149.03% |
+---------------------+-----------------------+-------------------------+------------------------+
| Rel Volume: 6.69 | Index: - | Short Ratio: 4.19 | ROI: -219.84% |
+---------------------+-----------------------+-------------------------+------------------------+
| RSI (14): 42.50 | Market Cap: 49.46M | Short Interest: 0.85M | Sales Surprise: -7.36% |
+---------------------+-----------------------+-------------------------+------------------------+
| ATR (14): 0.10 | Shs Outstand: 61.82M | Beta: 1.50 | EPS Surprise: -51.16% |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA20: -4.54% | Shs Float: 61.35M | Sales Q/Q: -13.45% | P/E: - |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA50: -25.16% | Inst Own: 20.65% | Sales past 5Y: 136.65% | Earnings: Mar 31 AMC |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA200: -23.76% | Insider Own: 0.75% | Employees: 41 | |
+---------------------+-----------------------+-------------------------+------------------------+
| Perf Week: 29.49% | Insider Trans: 6.92% | Debt/Eq: 0.51 | |
+---------------------+-----------------------+-------------------------+------------------------+

The next section covers any insider trading by Cue Biopharma officers or majority shareholders (if available).

Inside Trans: Cue Biopharma, Inc. (CUE) by Levisetti Matteo (Chief Medical Officer) on 2025-03-21
- Stock Option (right to buy): 250000 shares at $0 (D)

Inside Trans: Cue Biopharma, Inc. (CUE) by Warren Lucinda (CHIEF BUSINESS OFFICER) on 2025-03-21
- Stock Option (right to buy): 250000 shares at $0 (D)

Inside Trans: Cue Biopharma, Inc. (CUE) by Sandercock Colin (SVP, GENERAL COUNSEL) on 2025-03-21
- Stock Option (right to buy): 200000 shares at $0 (D)

Inside Trans: Cue Biopharma, Inc. (CUE) by Baker Daniel G. (CHIEF DEVELOPMENT OFFICER) on 2025-03-21
- Stock Option (right to buy): 100000 shares at $0 (D)

Inside Trans: Cue Biopharma, Inc. (CUE) by PASSERI DANIEL R (CHIEF EXECUTIVE OFFICER) on 2025-03-21
- Stock Option (right to buy): 450000 shares at $0 (D)

Inside Trans: Cue Biopharma, Inc. (CUE) by Millar Kerri-Ann (CHIEF FINANCIAL OFFICER) on 2025-03-21
- Stock Option (right to buy): 200000 shares at $0 (D)

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 9532000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -44612000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.8204
Average Volume: 169302.41
30-Day High: 1.03
30-Day Low: 0.6178

[Detailed Financials: Q3 2024]
- Total Assets: $44,810,000.0
- Total Liabilities: $19,444,000.0
- Total Equity: $25,366,000.0
- Current Assets: $37,256,000.0
- Current Liabilities: $16,790,000.0

[Income Statement: Q3 2024]
- Revenue: $3,336,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.17

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $2,392,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $42,329,000.0
- Total Liabilities: $20,707,000.0
- Total Equity: $21,622,000.0
- Current Assets: $33,900,000.0
- Current Liabilities: $16,459,000.0

[Income Statement: Q2 2024]
- Revenue: $2,658,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.2

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-11,000,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Cue Biopharma (CUE).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Cue Biopharma.

2) MARKET_SCORE[]
This conversation was initiated because CUE is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for CUE.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, CUE could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect CUE to increase 50% from its current price of $0.82, say: PRICE_TARGET[1.23]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Cue Biopharma.

11) ETHICAL_RATING[]
Rate Cue Biopharma’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

CUE_IN_41 [2025-04-15 09:51:04 -0400] 126 Bytes | 29 tokens | Cum: 7910 tkns (98.88% of 8k)
==========================================================================

====================================
[2025-04-15 09:51:04] # Analysis Completed
Elapsed Time: 47.47 seconds